On May 22, Tongji University convened the Symposium on the Development Strategy of Cardiology and held the inauguration ceremony for the State Key Laboratory of Cardiovascular Diseases at Shanghai East Hospital of Tongji University.

The laboratory was officially approved for construction in March 2023. It is positioned as an integrated innovation consortium that deeply connects government, industry, academia, research, and clinical application. With a development philosophy that equally emphasizes basic and applied research, it aims to achieve seamless integration of research and development, full-chain synergy from theoretical breakthroughs to technological inventions, and collaborative innovation across all sectors. The laboratory is dedicated to producing original, pioneering research outcomes that contribute to human health.

The lab is committed to building a complete innovation ecosystem that spans basic research, technological breakthroughs, clinical validation, and industrial application. Its research priorities include the theoretical exploration of cardiovascular diseases and the development of relevant technologies, materials, devices, and pharmaceuticals. With a long-term vision to become a global hub for theoretical advancement and technological innovation in cardiology, the laboratory is strategically aligned with the industrial cluster advantages of the Zhangjiang Medical Device Park.

To support this vision, the lab has established four advanced technological platforms: molecular and cellular biology diagnostics, cell/subcellular imaging and functional analysis, organ/tissue histochemistry and functional testing, and in vivo cardiac electrophysiology and function analysis. These platforms enable cross-scale research from the nanometer to decimeter level, forming a comprehensive R&D system that supports the entire innovation chain from foundational discoveries to industrial transformation.